HilleVax, Inc.
75 State Street, Suite 100—#9995
Boston, MA 02109
April 26, 2022
VIA EDGAR
Ms. Jane Park
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | HilleVax, Inc. |
Registration Statement on Form S-1
File No. 333-264159
Dear Ms. Park:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of HilleVax, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on April 28, 2022, or as soon as practicable thereafter.
Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
| Very truly yours, | ||
| HILLEVAX, INC. | ||
| By: | /s/ Robert Hershberg | |
| Robert Hershberg, M.D., Ph.D. | ||
| President and Chief Executive Officer | ||
| cc: | Tim Buchmiller, Securities and Exchange Commission |
Julie Sherman, Securities and Exchange Commission
Terence O’Brien, Securities and Exchange Commission
Robert Hershberg, M.D., Ph.D., HilleVax, Inc.
Cheston J. Larson, Latham & Watkins LLP
Matthew T. Bush, Latham & Watkins LLP